-

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2025 financial results and provide a business update.

A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English
Hashtags
#Earnings
#GILD
#GileadInvestorRelations
#GileadSciences
#QuarterlyResults
#Results

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com

Social Media Profiles
Gilead Sciences Facebook
Gilead Sciences Instagram
Gilead Sciences LinkedIn
Gilead Sciences YouTube
More News From Gilead Sciences, Inc.

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company’s long-standing work to address emerging infectious diseases.“At Gilead, we recognize the urgency and human toll of global health emergencie...

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

SAN FRANCISCO & FOSTER CITY, Calif.--(BUSINESS WIRE)--The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight against HIV/AIDS has always depended on more than medicine. It has required scientific innovation, public education, activism, compassion, commun...

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir. The ISLEND trials are evaluating the efficacy and safety of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) in...
Back to Newsroom